Project Summary / Abstract
Some exposures in ophthalmology may not have an immediate effect, but instead a lag is necessary. For
example, there is a literature on possible cataractogenic effects of corticosteroid eyedrops (CS) among uveitis
patients. However, the precise impact of dose and/or duration of use are unknown. Also, the lag between CS
administration and development of cataract is unknown. Another possible application is to study the effects of
dietary and/or supplement use on development of AMD, where a lag effect is also likely to occur. The goal of
specific aim 1 is to use latency analysis methods for ophthalmological endpoints. Latency methods have been
used in pharmacoepidemiology, but to our knowledge, have never been used for ophthalmologic endpoints.
The AREDS study was a landmark study in the epidemiology of AMD. A byproduct of this study was the
development of the AREDS severity scale which is an ordinal scale ranging from 1 for no AMD to 9+ for
advanced AMD (AAMD). The usual analysis for risk factors is a time-to-event analysis based on the Cox
Proportional Hazards Model, where the event is reaching grade 9+. This is a valid, but inefficient analysis.
There are many eyes (about 40%) which show changes (either an increase or decrease), but which don't
develop AAMD. There are risk factors which are associated with these changes, but all such changes are
treated as censored data and are considered “non-events”. In Aim 2, we propose to use an ordinal regression
model for changes between successive visits which would provide a more efficient use of the data. There have
been previous multi-state ordinal models proposed, but separate models are fit for each possible transition and
are not integrated into an overall assessment of risk for specific covariates. This has application not only for
AMD, but also for other ordinal scales used for other ophthalmologic conditions, such as diabetic retinopathy.
For Aim 3, we propose to continue our work on applying correlated data methods to risk prediction for
endpoints such as AUC. We will specifically compare methods for estimating AUC for small samples, extensive
numbers of tied prediction scores and presence of both bilateral and unilateral subjects. In addition, we will
incorporate clustered data methods for estimation of NRI, which to our knowledge, has never been done
before.
In Aim 4, we will continue our work on translation of clustered data methods for the eye research community
including (a) correlated data methods in survival analysis, (b) analysis of longitudinal binary ocular data, and
(c) sample size/power calculations based on the eye as the unit of analysis.
Public Health Relevance Statement
Project Narrative
This proposal will consider (a) latency (lag) effects of both harmful and beneficial effects of exposures in
ophthalmic studies (b) ordinal regression models to assess change in ordinal scales in longitudinal ophthalmic
scales, such as the AREDS severity scale as an alternative to survival analysis to precisely capture changes in
disease severity before a final endpoint (e.g., advanced AMD in studies of macular degenration, or total
blindness in studies of diabetic retinopathy) is reached (c) assessment of measures of discrimination and risk
reclassification when comparing risk models in ophthalmology using the eye as the unit of analysis, and (d)
translational work on clustered data methods for the eye research community with a focus on (a) survival
analysis, (b) binary longitudinal outcome data and (c) sample size/power estimation.
No Sub Projects information available for 5R01EY022445-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EY022445-10
Patents
No Patents information available for 5R01EY022445-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EY022445-10
Clinical Studies
No Clinical Studies information available for 5R01EY022445-10
News and More
Related News Releases
No news release information available for 5R01EY022445-10
History
No Historical information available for 5R01EY022445-10
Similar Projects
No Similar Projects information available for 5R01EY022445-10